Indirect Treatment Comparison of Venetoclax plus Rituximab with B-cell Receptor Inhibitors in Patients with Relapsed/Refractory Chronic Lymphocytic Leukaemia

被引：0
|
作者：
Mato, A. [1 ]
Follows, G. [2 ]
Sail, K. [3 ]
Diakite, I. [4 ]
Nicoloso, D. [4 ]
Dietz, B. [5 ]
Maher, J. [6 ]
Alexiou, D. [6 ]
Chirikov, V. [4 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Haematol, Cambridge, England
[3] AbbVie Inc, N Chicago, IL USA
[4] Pharmerit Int, Bethesda, MD USA
[5] AbbVie Deutschland GmbH & Ko KG, Ludwigshafen, Germany
[6] AbbVie, N Chicago, IL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH19-PO-0
引用
收藏
页码：91 / 92
页数：2
相关论文
共 50 条
  • [1] Comparison of venetoclax plus rituximab with B-cell receptor inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia: a systematic review and network Meta-analysis
    Molica, Stefano
    Giannarelli, Diana
    Shanafelt, Tait D.
    LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 955 - 958
  • [2] Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
    Seymour, John F.
    Ma, Shuo
    Brander, Danielle M.
    Choi, Michael Y.
    Barrientos, Jacqueline
    Davids, Matthew S.
    Anderson, Mary Ann
    Beaven, Anne W.
    Rosen, Steven T.
    Tam, Constantine S.
    Prine, Betty
    Agarwal, Suresh K.
    Munasinghe, Wijith
    Zhu, Ming
    Lash, L. Leanne
    Desai, Monali
    Cerri, Elisa
    Verdugo, Maria
    Kim, Su Young
    Humerickhouse, Rod A.
    Gordon, Gary B.
    Kipps, Thomas J.
    Roberts, Andrew W.
    LANCET ONCOLOGY, 2017, 18 (02): : 230 - 240
  • [3] Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia
    Yang, Lin
    Banerji, Versha
    LANCET ONCOLOGY, 2024, 25 (04): : 413 - 414
  • [4] Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia
    Dretzke, J.
    Barton, P.
    Kaambwa, B.
    Connock, M.
    Uthman, O.
    Bayliss, S.
    Meads, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 19 - 26
  • [5] Venetoclax plus rituximab for chronic lymphocytic leukaemia
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (05): : E233 - E233
  • [6] RITUXIMAB PLUS BENDAMUSTINE IN ELDERLY PATIENTS AFFECTED BY RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Lucania, A.
    Villa, M. R.
    Izzo, G. Nitrato
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [7] Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Seymour, J. F.
    Kipps, T. J.
    Eichhorst, B.
    Hillmen, P.
    D'Rozario, J.
    Assouline, S.
    Owen, C.
    Gerecitano, J.
    Robak, T.
    De la Serna, J.
    Jaeger, U.
    Cartron, G.
    Montillo, M.
    Humerickhouse, R.
    Punnoose, E. A.
    Li, Y.
    Boyer, M.
    Humphrey, K.
    Mobasher, M.
    Kater, A. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12): : 1107 - 1120
  • [8] Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
    Kater, Arnon P.
    Eichhorst, Barbara F.
    Owen, Carolyn J.
    Jaeger, Ulrich
    Chyla, Brenda
    Lefebure, Marcus
    Millen, Rosemary
    Jiang, Yanwen
    Thadani-Mulero, Maria
    Boyer, Michelle
    Seymour, John F.
    HEMASPHERE, 2024, 8 (08):
  • [9] Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
    Koenig, Kristin
    Dotson, Emily
    Sheredy, Shane
    Bhat, Seema A.
    Byrd, John C.
    Wiczer, Tracy
    Woyach, Jennifer
    Awan, Farrukh T.
    Rogers, Kerry A.
    BLOOD, 2019, 134
  • [10] The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia
    Eyre, Toby A.
    Roeker, Lindsey E.
    Fox, Christopher P.
    Gohill, Satyen H.
    Walewska, Renata
    Walter, Harriet S.
    Forconi, Francesco
    Broom, Angus
    Arumainathan, Arvind
    Brander, Danielle M.
    Allan, John N.
    Schuster, Stephen J.
    Hill, Brian T.
    Lansigan, Frederick
    Cheson, Bruce D.
    Lamanna, Nicole
    Coombs, Catherine C.
    Barr, Paul M.
    Skarbnik, Alan P.
    Shadman, Mazyar
    Ujjani, Chaitra S.
    Pearson, Laurie
    Pagel, John M.
    Jacobs, Ryan
    Mato, Anthony R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : 918 - 923
12345